fda compounding curbs

fda compounding curbs

3 Surprising Ways FDA Cuts Prescription Weight Loss

The FDA is cutting prescription weight-loss options by removing semaglutide, tirzepatide and liraglutide from the 503B bulk compounding list, a move projected to raise wholesale acquisition costs by 18% by mid-2026. This change means pharmacies will pay more for the drugs and patients may see higher copays, squeezing household budgets.